ClinicalTrials.gg
RecruitingNCT06193889Updated Jul 29, 2026

KYSA-6: A Study of Anti-CD19 Chimeric Antigen Receptor T-Cell Therapy, in Patients With Generalized Myasthenia Gravis

A Phase 2/3 interventional study of Standard of Care Treatment and Standard lymphodepletion regimen in Myasthenia Gravis and Generalized Myasthenia Gravis, sponsored by Kyverna Therapeutics. Recruiting at 22 sites in 6 countries. Open to participants aged 18 Years to 75 Years. Per ClinicalTrials.gov, last updated 2026-07-29.

Sponsored by Kyverna Therapeutics · Phase 2/3, Interventional, and Treatment

How we know

From the registry’s dates

  • Started Aug 2024; still recruiting 2 years 2 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2/3
Study type
Interventional
Enrollment
66
Allocation
Randomized
Ages
18 Years to 75 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 144 studies in Myasthenia Gravis with a site in United States — 53 open to participants now, 72 under way, 24 of them phase 3. Myasthenia Gravis · United States.

Planned enrollment
48th of 108
66 · median 56
Started
2024
with 22 others
Phase 2/3
6 of 144
5 open now
Primary completion
2027-09
later than 34 of 71 live
Registered
91st of 144
by date

Among the 144 studies in Myasthenia Gravis with a site in United States, this one is the 48th largest by planned enrollment of the 108 interventional ones that give a count, is one of 23 that started in 2024, is one of 6 in phase 2/3, reaches primary completion later than 34 of the 71 other live ones, and was the 91st registered.

Myasthenia Gravis

331 studies on the registry are indexed under Myasthenia Gravis; 145 are open to participants now.

Browse Myasthenia Gravis studies →

Open to participants now

53 of the 144 studies in Myasthenia Gravis with a site in United States are open now. Recruiting first, the newest first:

48 more — sign in →

All 53 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 104 Myasthenia Gravis studies recruiting now, 64 (62%) set no upper age limit and 23 (22%) stop at 75 or younger; 16 take children under 18; 13 take healthy volunteers.

This study: 18 Years to 75 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 144 studies in Myasthenia Gravis with a site in United States, or all of them as a file.
02

Study summary

A Study of the Anti-CD 19 Chimeric Antigen Receptor T Cell Therapy for Patients with Myasthenia Gravis

Read the detailed description

Myasthenia gravis (MG) is a chronic autoimmune disease that affects the neuromuscular junction and is characterized by muscle weakness. B cells play a role in MG, and the disease is characterized by the presence of autoantibodies such as anti-AChR and anti-MuSK antibodies. CD-19 target chimeric antigen receptor (CAR) T cells harness the ability of cytotoxic T cells to directly and specifically lyse target cells to effectively deplete both normal and autoreactive B cells in the circulation as well as impacted lymphoid and potentially non-lymphoid tissues. KYV-101 (mivocabtagene autoleucel [miv-cel])), a fully human anti-CD19 CAR T-cell therapy, will be investigated in adult subjects with myasthenia gravis (MG).

03

Conditions studied

  • Myasthenia Gravis
  • Generalized Myasthenia Gravis

Keywords

  • KYV-101
  • myasthenia gravis
  • autoimmune disease
  • anti-CD19 CAR-T Therapy
  • cellular therapy
  • MG
  • KYSA-6
  • KYV101-006
  • mivocabtagene autoleucel
  • miv-cel
04

Who can participate

Ages eligible
18 Years to 75 Years
Sexes eligible
All
Accepts healthy volunteers
No

Eligibility criteria

Key Inclusion Criteria

  1. Presence of autoantibodies to AChR or MuSK
  2. Myasthenia Gravis Foundation of America (MGFA) Class II-IV
  3. MG-Activities of Daily Living (MG-ADL) total score of ≥6 at screening and confirmed at baseline visit
  4. QMG total score of ≥11 at screening an confirmed at baseline visit
  5. Failed treatment with 2 or more /immunomodulatory therapies, or failed at least 1 immunosuppressive therapy and required chronic plasmapheresis, or IVIG (or subcutaneous or intramuscular Ig) to control symptoms
  6. On a stable dose of and/or other immunotherapies for ≥1 month prior to screening. For patients treated with azathioprine, a stable dose for ≥2 months prior to screening is required
  7. No change in dose of acetylcholinesterase inhibitors for ≥2 weeks prior to screening
  8. No use of intravenous immune globulin (IVIG) or plasmapheresis (PLEX) within 4 weeks of screening or pre-dose baseline (unless this is part of their SOC treatment regimen)
  9. No use of rituximab (or any other anti-CD20 or CD19 monoclonal antibody) within 12 weeks prior to screening
  10. Able and willing to attend the necessary visits to the study site

Key Exclusion Criteria

  1. Unable to washout or interrupt disease therapy prior to apheresis and/or baseline if required
  2. Co-occurring neurological autoimmune disease (ie, Lambert-Eaton Myasthenic Syndrome) or any disease affecting the neuromuscular junction or muscle causing weakness (eg, myositis, myopathy, motor neuropathy)
  3. History of stroke (with residual sequalae and/or risk for recurrence), seizure (even if well controlled on antiepileptics), neurodegenerative disease, altered mental status (unexplained and/or recent/current), or uncontrolled/severe psychiatric disease
  4. Any serious and/or uncontrolled medical condition that, in the investigator's judgment, would cause unacceptable safety risk, interfere with study procedures or results, or compromise compliance with the protocol, including but not limited to, cardiac or pulmonary disease
  5. History of primary immunodeficiency, organ or bone marrow transplant, or splenectomy
  6. Active, uncontrolled, viral, bacterial, or systemic fungal infection or recent history of repeated infections
  7. Thymectomy \<12 months of screening or planned during the study
  8. Prior treatment with gene therapy product or cellular immunotherapy (eg, CAR T) requiring vector integration and directed at any target
  9. Patients requiring chronic anticoagulation therapy that cannot be discontinued for medical procedures
Terms in these criteria, in plain language(5)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Allogeneic and autologous transplant

Stem cell (bone marrow) transplants. Allogeneic uses cells from a donor; autologous uses your own cells, collected earlier and given back.

05

Study design

Phase
Phase 2 / Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Single group
Masking
None (open label)
Enrollment
66 participants (estimated)

Study arms

  • Experimental
    KYV-101 CAR-T cells with lymphodepletion conditioning

    Phase 2: Dosing with KYV-101 CAR-T cells

    Drug: Standard lymphodepletion regimen · Biological: KYV-101

  • Experimental
    KYV-101 Treatment

    Phase 3

    Drug: Standard lymphodepletion regimen · Biological: KYV-101

  • Active comparator
    Standard of Care

    Phase 3 Optional crossover to receive KYV-101 Treatment after 24 weeks

    Drug: Standard of Care Treatment · Drug: Standard lymphodepletion regimen · Biological: KYV-101

Interventions

06

What researchers measure

Primary outcomes

  1. Incidence and severity of adverse events (AEs) and laboratory abnormalities (Phase 2)

    Time frame: 18 months

  2. Efficacy of KYV-101 via Myasthenia Gravis Activities of Daily Living (MG-ADL) change from baseline (Phase 2)

    Time frame: 24 weeks

  3. Efficacy of KYV-101 via Myasthenia Gravis Activities of Daily Living (MG-ADL) change from baseline for KYV-101 Treatment arm to Standard of Care arm (Phase 3)

    Time frame: 24 weeks

  4. Efficacy of KYV-101 via Quantitative Myasthenia Gravis (QMG) change from baseline for KYV-101 Treatment arm to Standard of Care arm (Phase 3)

    Time frame: 24 weeks

Secondary outcomes

  1. Efficacy of KYV-101 via Myasthenia Gravis Composite (MGC) score change from baseline for KYV-101 Treatment arm to Standard of Care arm (Phase 3)

    Time frame: 24 weeks

  2. Efficacy of KYV-101 via Percent change from baseline in anti acetylcholine receptors (anti-AChR) antibody levels for KYV-101 Treatment arm to Standard of Care arm (Phase 3)

    Time frame: 24 weeks

  3. Efficacy of KYV-101 via Percent change from baseline in anti muscle-specific tyrosine kinase (anti-MuSK) antibody levels for KYV-101 Treatment arm to Standard of Care arm (Phase 3)

    Time frame: 24 weeks

  4. Efficacy of KYV-101 via Proportion of patients with a ≥3 point improvement from baseline in Myasthenia Gravis Activities of Daily Living (MG-ADL) for KYV-101 Treatment arm to Standard of Care arm (Phase 3)

    Time frame: 24 weeks

  5. Efficacy of KYV-101 via Proportion of patients with minimal symptom expression (MSE) for KYV-101 Treatment arm to Standard of Care arm (Phase 3)

    Time frame: 24 weeks

  6. Efficacy of KYV-101 via Myasthenia Gravis Quality of Life 15-item Scale (MG-QoL 15r) change from baseline for KYV-101 Treatment arm to Standard of Care arm (Phase 3)

    Time frame: 24 weeks

  7. Incidence and severity of adverse events (AEs) and laboratory abnormalities (Phase 3)

    Time frame: 18 months

07

Study locations

22 of 22 sites recruiting
  • Ronald Reagan UCLA Medical Center
    Los Angeles, California 90095, United States
    Recruiting
    • Study Coordinator · Contact
  • University of California, Irvine
    Orange, California 92868, United States
    Recruiting
    • Study Coordinator · Contact
  • Stanford University Medical Center
    Palo Alto, California 94305, United States
    Recruiting
    • Study Coordinator · Contact
  • University of Miami
    Miami, Florida 33149, United States
    Recruiting
    • Study Coordinator · Contact
  • Indiana University Health
    Indianapolis, Indiana 46202, United States
    Recruiting
    • Study Coordinator · Contact
  • University of Missouri
    Columbia, Missouri 65212, United States
    Recruiting
    • Study Coordinator · Contact
  • Oregon Health & Science University
    Portland, Oregon 97239, United States
    Recruiting
    • Study Coordinatory · Contact
  • Thomas Jefferson University Hospital
    Philadelphia, Pennsylvania 19107, United States
    Recruiting
    • Study Coordinator · Contact
  • Houston Methodist Hospital
    Houston, Texas 77030, United States
    Recruiting
    • Study Coordinator · Contact
  • Intermountain Medical Center
    Murray, Utah 84107, United States
    Recruiting
    • Study Coordinator · Contact
  • Westmead Institute for Medical Research
    Westmead, Australia
    Recruiting
    • Study Coordinator · Contact
  • Hospital Israelita Albert Einstein
    São Paulo, Brazil
    Recruiting
    • Study Coordinator · Contact
  • Charite- Universitätsklinikum Berlin
    Berlin, Germany
    Recruiting
    • Study Coordinator · Contact
  • Universitätsklinikum der Ruhr-Universität Bochum
    Bochum, Germany
    Recruiting
    • Study Coordinator · Contact
  • Universitätsklinikum Hamburg-Eppendorf
    Hamburg, Germany
    Recruiting
    • Study Coordinator · Contact
  • Medizinische Hochscule Hannover
    Hanover, Germany
    Recruiting
    • Study Coordinator · Contact
  • Friedrich-Schiller-Universität Jena
    Jena, Germany
    Recruiting
    • Study Coordinator · Contact
  • Universitätsklinik Magdeburg
    Magdeburg, Germany
    Recruiting
    • Study Coordinator · Contact
  • Technical University Munich, Klinikum Rechts der Isar
    Munich, Germany
    Recruiting
    • Study Coordinator · Contact
  • King's Faisal Specialist Hospital and Research Center
    Riyadh, Kindom of Saudi Arabia, Saudi Arabia
    Recruiting
    • Study Coordinator · Contact
  • Cambridge University Hospital, Addenbrooke's Hospital
    Cambridge, United Kingdom
    Recruiting
    • Study Coordinator · Contact
  • King's College Hospital
    London, United Kingdom
    Recruiting
    • Study Coordinator · Contact
08

References and documents

Publications

  • Gilhus NE, Tzartos S, Evoli A, Palace J, Burns TM, Verschuuren JJGM. Myasthenia gravis. Nat Rev Dis Primers. 2019 May 2;5(1):30. doi: 10.1038/s41572-019-0079-y. PubMed 31048702 ↗

Individual participant data

Plan to share: No

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Started Aug 2024 (actual). Primary completion is estimated for Sep 2027, 37 months after the start.

How these figures are worked out, and which studies are left out of them.

Registered
Oct 11, 2023
First posted
Jan 5, 2024
StartActual
Aug 28, 2024
Primary completionEst.
Sep 2027
CompletionEst.
Sep 2028
Last update
Jul 29, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jul 29, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06193889
Lead sponsor
Kyverna Therapeutics
Responsible party
Sponsor
First posted
Jan 5, 2024
Start date
Aug 28, 2024
Primary completion
Sep 2027 (estimated)
Completion
Sep 2028 (estimated)
Last update
Jul 29, 2026

Study contacts

Kyverna Therapeutics, Inc.
Contact
Clinicaltrials@kyvernatx.com
510-925-2484
MD
study director · Kyverna Therapeutics, Inc.

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Mivocabtagene autoleucel

Start the discussion